Patients with type 1 diabetes treated with the monoclonal antibody teplizumab (MacroGenics, Inc.) exhibit greater preservation of C-peptide, a biomarker of islet cell function, compared to controls, according to the primary results from a new clinical trial. Further analyses identified a discrete subset of the treatment group that demonstrated especially robust responses ("responders"), suggesting that these patients could be identified prior to treatment. The trial, entitled ...Saturday, 17 August 2013
Subset of Patients With Strong Response to Therapy Identified By ITN Type 1 Diabetes Study
Patients with type 1 diabetes treated with the monoclonal antibody teplizumab (MacroGenics, Inc.) exhibit greater preservation of C-peptide, a biomarker of islet cell function, compared to controls, according to the primary results from a new clinical trial. Further analyses identified a discrete subset of the treatment group that demonstrated especially robust responses ("responders"), suggesting that these patients could be identified prior to treatment. The trial, entitled ...
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment